Six degrees of separation: The oxygen effect in the development of radiosensitizers

Translational Oncology

Volumn 4, Issue 4, 2011, Pages 189-198

  Oronsky, Bryan T ^a   Knox, Susan J ^b   Scicinski, Jan ^a  

^a RadioRx Inc   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APAZIQUONE; BANOXANTRONE; CARBOGEN; CARBOPLATIN; CD47 ANTIGEN; CISPLATIN; CYTOTOXIN; EFAPROXIRAL; ERYTHROPOIETIN; GADOLINIUM TEXAPHYRIN; HYALURONIC ACID; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INHIBITOR OF APOPTOSIS PROTEIN; MITOMYCIN; NICOTINAMIDE; NITRIC OXIDE; NITROIMIDAZOLE DERIVATIVE; OXALIPLATIN; OXYGEN; PLATINUM COMPLEX; PORFIROMYCIN; RADIOSENSITIZING AGENT; SURVIVIN; THROMBOSPONDIN 1; TIRAPAZAMINE; TRANSITION ELEMENT; UNINDEXED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLOOD TRANSFUSION; BRAIN METASTASIS; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; HEAD AND NECK CANCER; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; LINEAR ENERGY TRANSFER; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOSENSITIZATION; REVIEW; SKIN CANCER; TUMOR CELL; UTERINE CERVIX CANCER;

EID: 79960313911     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11166     Document Type: Review

References (126)

1. Bel Aiba RS, Dimova EY, Görlach A, and Kietzmann T (2006). The role of hypoxia inducible factor-1 in cell metabolism-a possible target in cancer therapy. Expert Opin Ther Targets 10, 583-599.
2. Boyle RG and Travers S (2006). Hypoxia: targeting the tumour. Anticancer Agents Med Chem 6, 281-286.
3. Maxwell PH (2005). The HIF pathway in cancer. Semin Cell Dev Biol 16, 523-530.
4. Williams KJ, Cowen RL, and Stratford IJ (2001). Hypoxia and oxidative stress. Tumour hypoxia-therapeutic considerations. Breast Cancer Res 3, 328-331.
5. Vaupel P, Schlenger K, Knoop C, and Höckel M (1991). Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51, 3316-3322.
6. Daşu A and Denekamp J (1998). New insights into factors influencing the clinically relevant oxygen enhancement ratio. Radiother Oncol 46, 269-277.
7. Thomlinson RH and Gray LH (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549.
8. Mayer R, Hamilton-Farrell MR, van der Kleij AJ, Schmutz J, Granström G, Sicko Z, Melamed Y, Carl UM, Hartmann KA, Jansen EC, et al. (2005). Hyperbaric oxygen and radiotherapy. Strahlenther Onkol 181, 113-123.
9. Hoskin P, Rojas A, and Saunders M(2009). Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys 73, 1425-1431.
10. Kaanders JH, Bussink J, and van der Kogel AJ (2002). ARCON: a novel biologybased approach in radiotherapy. Lancet Oncol 3, 728-737.
11. Varlotto J and Stevenson MA (2005). Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63, 25-36.
12. Dicato M and Plawny L (2010). Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol 22, 307-311.
13. Suh JH, Stea B, Tankel K, Marsiglia H, Belkacemi Y, Gomez H, Falcone- Lizaraso S, May J, and Saunders M (2008). Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with Whole Brain Radiation Therapy (WBRT) in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys 72, S50-S51.
14. Sihn G, Walter T, Klein JC, Queguiner I, Iwao H, Nicolau C, Lehn JM, Corvol P, and Gasc JM (2007). Anti-angiogenic properties of myo-inositol trispyrophosphate in ovo and growth reduction of implanted glioma. FEBS Lett 581, 962-966.
15. Kieda C, Greferath R, Crola da Silva C, Fylaktakidou KC, Lehn JM, and Nicolau C (2006). Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc Natl Acad Sci USA 103, 15576-15581.
16. Ogawa Y, Ue H, Tsuzuki K, Tadokoro M, Miyatake K, Sasaki T, Yokota N, Hamada N, Kariya S, Hitomi J, et al. (2008). New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep 19, 1389-1394.
17. Miyatake K, Kubota K, Ogawa Y, Hamada N, Murata Y, and Nishioka A (2010). Non-surgical care for locally advanced breast cancer: radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy. Oncol Rep 24, 1161-1168.
18. Ogawa Y, Kubota K, Ue H, Kataoka Y, Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J, et al. (2009). Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radio sensitization treatment, Kochi Oxydol- Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol 34, 609-618.
19. Brown JM (1975). Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582. Radiat Res 64, 633-647.
20. Dische S, Saunders MI, Lee ME, Adams GE, and Flockhart IR (1977). Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer 35, 567-579.
21. Brown JM (1984). Clinical trials of radiosensitizers: what should we expect? Int J Radiat Oncol Biol Phys 10, 425-429.
22. Rosenberg A and Knox S (2006). Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys 64, 343-354.
23. Rao DN and Mason RP (1987). Generation of nitro radical anions of some 5- nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs. J Biol Chem 262, 11731-11736.
24. Hammami N, Drissi C, Sebai R, Araar M, Maatallah Y, Belghith L, Nagi S, Hentati F, and Ben Hamouda M (2007). Reversible metronidazole-induced encephalopathy. J Neuroradiol 34, 133-136.
25. Ahmed A, Loes DJ, and Bressler EL (1995). Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy. Neurology 45, 588-589.
26. Dobrowsky W, Huigol NG, Jayatilake RS, Kizilbash NI, Okkan S, Kagiya VT, and Tatsuzaki H (2007). AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomized trial. Radiother Oncol 82, 24-29.
27. Brown JM and Wilson WR (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 437-447.
28. Liu TZ, Lin TF, Chiu DT, Tsai KJ, and Stern A (1997). Palladium or platinum exacerbates hydroxyl radical mediated DNA damage. Free Radic Biol Med 23, 155-161.
29. Shen L, Lan Z, Sun X, Shi L, Liu Q, and Ni J (2010). Proteomic analysis of lanthanum citrate-induced apoptosis in human cervical carcinoma SiHa cells. Biometals 23, 1179-1189.
30. Kostova I (2005). Lanthanides as anticancer agents. Curr Med Chem Anticancer Agents 5, 591-602.
31. Magda D, Lepp C, Gerasimchuk N, Lee I, Sessler JL, Lin A, Biaglow JE, and Miller RA (2001). Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 51, 1025-1036.
32. Sessler JL and Miller RA (2000). Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. BiochemPharmacol 59, 733-739.
33. Adis International, Limited (2004). Motexafin gadolinium: gadolinium(III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120. Drugs RD 5, 52-57.
34. Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL, Miller R, Engel J, Young S, Miles D, et al. (1999). A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5, 739-745.
35. Xu S, Zakian K, Thaler H, Matei C, Alfieri A, Chen Y, and Koutcher JA (2001). Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 49, 1381-1390.
36. Bernhard EJ, Mitchell JB, Deen D, Cardell M, Rosenthal DI, and Brown JM (2000). Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Res 60, 86-91.
37. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, et al. (2003). Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21, 2529-2536.
38. Lin AJ, Cosby LA, Shansky CW, and Sartorelli AC (1972). Potential bioreductive alkylating agents. 1. Benzoquinone derivatives. J Med Chem 15, 1247-1252.
39. Pan SS and Gonzalez H (1990). Mitomycin antibiotic reductive potential and related pharmacological activities. Mol Pharmacol 37, 966-970.
40. Lavaggi ML, Cabrera M, González M, and Cerecetto H (2008). Differential enzymatic reductions governing the differential hypoxia-selective cytotoxicities of phenazine 5,10-dioxides. Chem Res Toxicol 21, 1900-1906.
41. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, and Lewis AD (1996). Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88, 259-269.
42. Pruijn FB, Sturman JR, Liyanage HD, Hicks KO, Hay MP, and Wilson WR (2005). Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J Med Chem 48, 1079-1087.
43. Siim BG, Atwell GJ, Anderson RF, Wardman P, Pullen SM, Wilson WR, and Denny WA (1997). Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs. J Med Chem 40, 1381-1390.
44. De RidderM, Van EschG, Engels B, Verovski V, and Storme G(2008).Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway. Bull Cancer 95, 282-291.
45. Moore HW (1977). Bioactivation as a model for drug design bioreductive alkylation. Science 197, 527-532.
46. Iyer VN and Szybalski W (1964). Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of dna. Science 145, 55-58.
47. Keyes SR, Rockwell S, and Sartorelli AC (1985). Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 45, 3642-3645.
48. Rockwell S, Hughes CS, Keyes SR, Sartorelli AC, and Kennedy KA (1993). Porfiromycin as an adjunct to radiotherapy in young and old mice. Exp Gerontol 28, 281-293.
49. Rockwell S, Keyes SR, and Sartorelli AC (1988). Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 116, 100-113.
50. Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, et al. (2005). Concurrent chemo-radiotherapy with mito mycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol BiolPhys 61, 119-128.
51. Haffty BG, Son YH, Wilson LD, Papac R, Fischer D, Rockwell S, Sartorelli AC, Ross D, Sasaki CT, and Fischer JJ (1997). Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5, 235-245.
52. Witjes JA and Kolli PS (2008). Apaziquone for non-muscle invasive bladder cancer: a critical review. Expert Opin Investig Drugs 17, 1085-1096.
53. Workman P (1994). Enzyme-directed biore ductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinine anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6, 461-475.
54. Walton MI, Sugget N, andWorkman P (1992). The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 22, 643-647.
55. Walton MI, Bibby MC, Double JA, Plumb JA, and Workman P (1992). DT diaphorase activity correlates with sensitivity to the indo loquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 28A, 1597-1600.
56. Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, Koier I, Krediet RT, Stoter G, and Verweij J (1994). Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst 86, 906-912.
57. Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, and Puri R (2009). Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73, 1083-1086.
58. Hendricksen K, van der Heijden AG, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Smits GA, Puri R, Gruijs S, and Witjes JA (2009). Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 27, 337-342.
59. Spectrum Pharma. Available at http://www.spectrumpharma.com/eoquin.html Accessed June 19, 2011.
60. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, and Lee WW(1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12, 1239-1242.
61. Brown JM (1993). SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67, 1163-1170.
62. Brown JM and Lemmon MJ (1991). Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int J Radiat Oncol Biol Phys 20, 457-461.
63. Reddy SB and Williamson SK (2009). Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 18, 77-87.
64. Huxham LA, Kyle AH, Baker JH, McNicol KL, and Minchinton AI (2008). Exploring vascular dysfunction caused by tirapazamine. Microvasc Res 75, 247-255.
65. Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, Anderson RF, Shinde SS, Wilson WR, and Denny WA (2008). Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. J Med Chem 51, 6853-6865.
66. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, et al. (2010). Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 16, 4946-4957.
67. Hicks KO, Pruijn FB, Secomb TW, Hay MP, Hsu R, Brown JM, Denny WA, Dewhirst MW, and Wilson WR (2006). Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxiatargeted anticancer drugs. J Natl Cancer Inst 98, 1118-1128.
68. Nishida CR and Ortiz de Montellano PR (2008). Reductive heme-dependent activation of the n-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem 51, 5118-5120.
69. Patterson LH and McKeown SR (2000). AQ4N: a new approach to hypoxiaactivated cancer chemotherapy. Br J Cancer 83, 1589-1593.
70. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, and Stratford IJ (2000). Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82, 1984-1990.
71. Hejmadi MV, McKeown SR, Friery OP, McIntyre IA, Patterson LH, and Hirst DG (1996). DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer 73, 499-505.
72. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, and Hirst DG (1996). Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer Suppl 27, S39-S42.
73. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, and Patterson LH (1995). AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 72, 76-81.
74. Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, Milián ML, Mani S, Tolcher A, Lalani AS, et al. (2008). A phase 1 open-label, accelerated doseescalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 14, 7110-7115.
75. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N, Alcock C, Anthoney A, Vjaters E, Dunk CR, et al. (2008). Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 14, 1096-1104.
76. Sarantopoulos JJ, Tolcher AW, Wong A, Goel S, Beeram M, Lam G, Desai K, Woody K, Mani S, and Papadopoulos KP (2006). Banoxantrone (AQ4N), tissue CYP 450 targeted prodrug: the results of a phase I study using an accelerated dose escalation. J Clin Oncol 24, 2011.
77. Wang GL and Semenza GL (1993). General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90, 4304-4308.
78. Semenza GL (2006). Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 10, 267-280.
79. Koh MY, Spivak-Kroizman TR, and Powis G (2009). Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res 15, 5945-5946.
80. Onnis B, Rapisarda A, and Melillo G (2009). Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13, 2780-2786.
81. Palayoor ST, Mitchell JB, Cerna D, Degraff W, John-Aryankalayil M, and Coleman CN (2008). PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 123, 2430-2437.
82. Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, et al. (2010). Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J ThoracOncol 5, 940-949.
83. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, and Powis G (2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7, 90-100.
84. Tibes R, Falchook GS, Von Hoff DD, Weiss GJ, Iyengar T, Kurzrock R, Pestano L, Lowe AM, and Herbst RS (2010). Results from a phase I, doseescalation study of PX-478, an orally available inhibitor of HIF-1a. J Clin Oncol 28(suppl), 3076.
85. Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, and Powis G (2010). Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 9, 2057-2067.
86. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, et al. (2009). The selective hypoxia induciblefactor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 8, 947-958.
87. Salvesen GS and Duckett CS (2002). IAP proteins: blocking the road to death'sdoor. Nat Rev Mol Cell Biol 3, 401-410.
88. Wei H, Wang C, and Chen L (2006). Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha. Pancreas 32, 159-163.
89. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, and Reed JC (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58, 5315-5320.
90. Cao C, Mu Y, Hallahan DE, and Lu B (2004). XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23, 7047-7052.
91. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, and LaCasse EC (2003). Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lungcancer cells in vitro and in vivo. Clin Cancer Res 9, 2826-2836.
92. Olie RA, Simões-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA, and Zangemeister-Wittke U (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60, 2805-2809.
93. Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, et al. (2011). Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci 102, 324-329.
94. Survivin vaccine therapy for patients with malignant gliomas. Available at: Clinicaltrialsfeeds.org/clinical-trials/show/NCT01250470.Accessed June 19, 2011.
95. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, et al. (2008). Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51, 2412-2420.
96. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, et al. (2010). Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116, 1524-1527.
97. Li S, Zhang J, Li J, Chen D, Matteucci M, Curd J, and Duan JX (2010). Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302. Biol Trace Elem Res 136, 294-301.
98. Bischoff P, Altmeyer A, and Dumont F (2009). Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat 19, 643-662.
99. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. (2010). The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70, 1573-1584.
100. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, and Wilson WR(2007). Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 69, 560-571.
101. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, and Wilson WR (2010). A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65, 791-801.
102. Proacta Updates PR1-4 Phase II Program, Vol. 2010. Available at: http://www.proacta.com/news/pr_feb0110.htm. Accessed June 19, 2011.
103. Edfeldt NB, Harwood EA, Sigurdsson ST, Hopkins PB, and Reid BR (2004). Solution structure of a nitrous acid induced DNA interstrand cross-link. Nucleic Acids Res 32, 2785-2794.
104. Bonavida B, Khineche S, Huerta-Yepez S, and Garbán H (2006). Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 9, 157-173.
105. Nelson EJ, Connolly J, and McArthur P (2003). Nitric oxide and S-nitrosylation: excitotoxic and cell signaling mechanism. Biol Cell 95, 3-8.
106. 2+)-independent synaptic vesicle release. Neuron 12, 1235-1244.
107. Tayeh MA and Marletta MA (1989). Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 264, 19654-19658.
108. Brüne B (2003). Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 10, 864-869.
109. Bonavida B and Baritaki S (2011). Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-κB/Snail/YY1/RKIPcircuitry. Nitric Oxide 24, 1-7.
110. Shan SQ, Rosner GL, Braun RD, Hahn J, Pearce C, and Dewhirst MW (1997). Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 76, 429-437.
111. Frederiksen LJ, Sullivan R, Maxwell LR, Macdonald-Goodfellow SK, Adams MA, Bennett BM, Siemens DR, and Graham CH (2007). Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 13, 2199-2206.
112. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, and Yeung K (2008). Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and mmunosensitization to apoptosis and inhibition of metastases. Nitric Oxide 19, 152-157.
113. Gao X, Saha D, Kapur P, Anthony T, Livingston EH, and Huerta S (2009). Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate. J Surg Oncol 100, 149-158.
114. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, and Gallez B (2000). Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 48, 565-570.
115. Girard M, Clairmont F, Maneckjee A, Mousseau N, Dawson B, and Whitehouse L (1993). 5-Nitroimidazoles. II: Unexpected reactivity of ronidazole and dimetridazole with thiols. Can J Chem 71, 1349-1352.
116. Kondakova IV, Tcheredova VV, Zagrebelnaya GV, Cherdyntseva NV, Kagiya TV, and Choinzonov EL (2004). Production of nitric oxide by hypoxic radiosensitizer sanazole. Exp Oncol 26, 329-333.
117. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, and Hoskin PJ (2007). Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8, 111-118.
118. Siemens DR, Heaton JP, Adams MA, Kawakami J, and Graham CH (2009). Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 74, 878-883.
119. Isenberg JS, Martin-Manso G, Maxhimer JB, and Roberts DD (2009). Regulation of nitric oxide signalling by thrombospondin 1: implications for antiangiogenic therapies. Nat Rev Cancer 9, 182-194.
120. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, and Roberts DD (2007). Increasing survival of ischemic tissue by targeting CD47. Circ Res 100, 712-720.
121. Libert N, Tourtier JP, Védrine L, and Chargari C (2010). Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists. Anesthesiology 113, 704-712.
122. Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, Tsokos M, Wink DA, and Roberts DD (2008). Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 173, 1100-1112.
123. Liebmann J, DeLuca AM, Coffin D, Keefer LK, Venzon D, Wink DA, and Mitchell JB (1994). In vivo radiation protection by nitric oxide modulation. Cancer Res 54, 3365-3368.
124. Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, and Knox S (2011). Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials [abstract]. In Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research, Orlando, Florida, 2-6 April 2011. Philadelphia (PA): AACR. Abstract 676.
125. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, Tsokos M, Wink DA, Isenberg JS, and Roberts DD (2009). Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 1, 3-7.
126. Overgaard J (2007). Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25, 4066-4074.